Table 4.
Association of N1-MN + 2Py excretion with risk of mortality in subgroups of serum hs-CRP in KTR 1.
| Model | Hs-CRP ≤ 3 mg/L | Hs-CRP > 3 mg/L | ||
|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| All-Cause Mortality | ||||
| 1 2 | 0.46 (0.34–0.64) | <0.001 | 0.64 (0.44–0.95) | 0.03 |
| 2 3 | 0.48 (0.34–0.68) | <0.001 | 0.79 (0.52–1.20) | 0.27 |
| 3 4 | 0.49 (0.35–0.68) | <0.001 | 0.80 (0.53–1.21) | 0.29 |
| 4 5 | 0.50 (0.35–0.72) | <0.001 | 0.89 (0.57–1.39) | 0.61 |
| 5 6 | 0.58 (0.42–0.82) | 0.002 | 0.83 (0.54–1.26) | 0.37 |
| 6 7 | 0.57 (0.41–0.81) | 0.002 | 0.83 (0.54–1.27) | 0.38 |
| 7 8 | 0.56 (0.38–0.83) | 0.003 | 0.90 (0.57–1.42) | 0.64 |
| Events (n) | 81 | 62 | ||
| Infectious Mortality | ||||
| 1 2 | 0.35 (0.20–0.60) | <0.001 | 0.60 (0.28–1.32) | 0.21 |
| 2 3 | 0.38 (0.21–0.67) | 0.001 | 0.71 (0.30–1.65) | 0.43 |
| 3 4 | 0.39 (0.22–0.67) | 0.001 | 0.70 (0.30–1.64) | 0.41 |
| 4 5 | 0.38 (0.21–0.70) | 0.002 | 0.97 (0.39–2.43) | 0.95 |
| 5 6 | 0.47 (0.27–0.83) | 0.009 | 0.79 (0.34–1.84) | 0.58 |
| 6 7 | 0.45 (0.25–0.81) | 0.008 | 0.77 (0.31–1.89) | 0.56 |
| 7 8 | 0.40 (0.20–0.78) | 0.008 | 0.79 (0.34–1.81) | 0.58 |
| Events (n) | 25 | 15 | ||
| Noninfectious Mortality | ||||
| 1 2 | 0.53 (0.36–0.78) | 0.001 | 0.66 (0.42–1.02) | 0.06 |
| 2 3 | 0.54 (0.36–0.83) | 0.005 | 0.82 (0.51–1.31) | 0.41 |
| 3 4 | 0.54 (0.36–0.83) | 0.005 | 0.84 (0.52–1.34) | 0.46 |
| 4 5 | 0.57 (0.37–0.90) | 0.02 | 0.87 (0.52–1.44) | 0.58 |
| 5 6 | 0.65 (0.42–0.98) | 0.04 | 0.84 (0.51–1.37) | 0.48 |
| 6 7 | 0.64 (0.42–0.97) | 0.04 | 0.82 (0.51–1.31) | 0.41 |
| 7 8 | 0.66 (0.42–1.05) | 0.08 | 0.95 (0.55–1.65) | 0.87 |
| Events (n) | 56 | 47 | ||
1 The association of N1-MN + 2Py excretion with risk of all-cause mortality, infectious mortality, and noninfectious mortality in KTR was investigated with Cox regression analyses, with adjustment for potential confounders. 2 Model 1: adjusted for sex. 3 Model 2: adjusted as for model 1 and for age and body surface area. 4 Model 3: adjusted as for model 2 and for serum hs-CRP. 5 Model 4: adjusted as for model 2 and for plasma vitamin B6. 6 Model 5: adjusted as for model 2 and for eGFR, proteinuria, and primary renal disease. 7 Model 6: adjusted as for model 2 and for use of proliferation inhibitors, acetylsalicylic acid, and proton pump inhibitors. 8 Model Model 7: adjusted as for model 2 and for intake of alcohol and energy. CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; N1-MN, N1-methylnicotinamide; KTR, kidney transplant recipients; 2Py, N1-methyl-2-pyridone-5-carboxamide.